Our mission is to address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.

We plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

Latest News
Mar 10, 2020
Eyevensys Announces Executive Leadership Team Expansion

1.       Gerald Cagle, Ph.D. named Chairman of the Board

2.       Francine Behar-Cohen, M.D., Ph.D. named...

Jan 8, 2020
Eyevensys Closes $30M Series B Financing

Paris, France, and Fort Worth, Texas, United States, January 8, 2020 – Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene...